A study published in Menopause found that initiating hormone therapy after age 65 is associated with increased risks for any cancer and cerebrovascular accidents. The analysis of 83,147 women also showed elevated hazards for cancer and vascular events among those who initiated HT at ages 50 to 65.
A study of over 83,000 women found that initiating hormone therapy after age 65 significantly increases risks for cancer and cerebrovascular events, reinforcing current guidelines that discourage starting systemic hormone therapy after age 60.
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
